Effect of Liraglutide on Blood Pressure: a Meta-analysis of Liraglutide Randomized Controlled Trials

Overview

Journal BMC Endocr Disord

Publisher Biomed Central

Specialty Endocrinology

Date 2019 Jan 9

PMID 30616638

Citations 11

Authors

Xu Zhao

Kun Huang

Meijie Zheng

Junting Duan

Affiliations

Soon will be listed here.

Abstract

Background: Several clinical trials have studied the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on glycometabolism and cardiovascular risk factors since they were identified. Because of their cardiovascular benefits and efficacy in lowering glucose, GLP-1RAs are becoming increasingly important in clinical therapy for patients with or without pathoglycaemia. The aim of this study was to assess the effect of the GLP-1RA liraglutide on blood pressure based on randomised controlled trials (RCTs).

Methods: We searched PubMed for RCTs published from 2009 to 2018 comparing the effect of liraglutide on blood pressure with that of placebo in individuals with or without pathoglycaemia. RCTs in humans that included data describing blood pressure changes from baseline to the end of the trial were selected for inclusion in the meta-analysis.

Results: A total of 18 RCTs that enrolled 7616 individuals in the liraglutide group and 6046 individuals in the control group were included in this meta-analysis. Compared with placebo, liraglutide reduced systolic blood pressure (SBP) by 3.18 mmHg (95% CI -4.32, - 2.05), P < 0.00001, but had no significant effect on diastolic blood pressure (DBP). Subgroup analysis showed that the degree of reduction in SBP was associated with the dose of liraglutide but that significance disappeared when the intervention lasted over 1 year. Liraglutide 3.0 mg/d significantly reduced DBP by 1.46 mmHg (95% CI -2.61, 0.32), P = 0.01, but liraglutide 1.8 mg/d slightly increased DBP by 0.47 mmHg (95% CI 0.11, 0.83), P = 0.01, compared with placebo.

Conclusions: This meta-analysis demonstrated that liraglutide significantly reduced SBP in individuals with or without pathoglycaemia compared with placebo, but the difference was no longer significant when the intervention lasted over 1 year. Moreover, the effect of liraglutide on blood pressure is associated with the dose. This finding may provide additional evidence for cardiovascular protection.

Citing Articles

Pharmacologic Treatment of Obesity in adults and its impact on comorbidities: 2024 Update and Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of....

Moreira R, Valerio C, Hohl A, Moulin C, Moura F, Trujilho F Arch Endocrinol Metab. 2024; 68():e240422.

PMID: 39664998 PMC: 11634287. DOI: 10.20945/2359-4292-2024-0422.

Impact of GLP-1 Receptor Agonists on Psoriasis and Cardiovascular Comorbidities: A Narrative Review.

Haran K, Johnson C, Smith P, Venable Z, Kranyak A, Bhutani T Psoriasis (Auckl). 2024; 14:143-152.

PMID: 39564576 PMC: 11575455. DOI: 10.2147/PTT.S485061.

The role of glucagon-like peptide-1/GLP-1R and autophagy in diabetic cardiovascular disease.

Guo Z Pharmacol Rep. 2024; 76(4):754-779.

PMID: 38890260 DOI: 10.1007/s43440-024-00609-1.

Switching from Multiple Insulin Injections to a Fixed Combination of Degludec and Liraglutide in Patients with Type 2 Diabetes Mellitus: Results from the Simplify Study After 6 Months.

Martinka E, Dravecka I, Tkac I Diabetes Ther. 2023; 14(9):1503-1515.

PMID: 37402960 PMC: 10363096. DOI: 10.1007/s13300-023-01435-z.

The Roles of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists and Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Decreasing the Occurrence of Adverse Cardiorenal Events in Patients With Type 2 Diabetes.

Shami D, Sousou J, Batarseh E, Alazrai L Cureus. 2023; 15(1):e33484.

PMID: 36751181 PMC: 9901266. DOI: 10.7759/cureus.33484.

References

Chobanian A, Bakris G, Black H, Cushman W, Green L, Izzo Jr J . The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289(19):2560-72. DOI: 10.1001/jama.289.19.2560. View

Yu M, Moreno C, Hoagland K, Dahly A, Ditter K, Mistry M . Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens. 2003; 21(6):1125-35. DOI: 10.1097/00004872-200306000-00012. View

Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews D . Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care. 2004; 27(6):1335-42. DOI: 10.2337/diacare.27.6.1335. View

Pickering T, Hall J, Appel L, Falkner B, Graves J, Hill M . Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart.... Hypertension. 2004; 45(1):142-61. DOI: 10.1161/01.HYP.0000150859.47929.8e. View

Gutzwiller J, Hruz P, Huber A, Hamel C, Zehnder C, Drewe J . Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans. Digestion. 2006; 73(2-3):142-50. DOI: 10.1159/000094334. View

Basu A, Charkoudian N, Schrage W, Rizza R, Basu R, Joyner M . Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab. 2007; 293(5):E1289-95. DOI: 10.1152/ajpendo.00373.2007. View

Patel A, Macmahon S, Chalmers J, Neal B, Woodward M, Billot L . Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007; 370(9590):829-40. DOI: 10.1016/S0140-6736(07)61303-8. View

Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mohanty P, Dandona P . Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract. 2007; 13(5):444-50. DOI: 10.4158/EP.13.5.444. View

Ban K, Noyan-Ashraf M, Hoefer J, Bolz S, Drucker D, Husain M . Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008; 117(18):2340-50. DOI: 10.1161/CIRCULATIONAHA.107.739938. View

10.

Nauck M, Frid A, Hermansen K, Shah N, Tankova T, Mitha I . Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2008; 32(1):84-90. PMC: 2606836. DOI: 10.2337/dc08-1355. View

11.

Zinman B, Gerich J, Buse J, Lewin A, Schwartz S, Raskin P . Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009; 32(7):1224-30. PMC: 2699702. DOI: 10.2337/dc08-2124. View

12.

Marre M, Shaw J, Brandle M, Bebakar W, Kamaruddin N, Strand J . Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. 2009; 26(3):268-78. PMC: 2871176. DOI: 10.1111/j.1464-5491.2009.02666.x. View

13.

Russell-Jones D, Vaag A, Schmitz O, Sethi B, Lalic N, Antic S . Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009; 52(10):2046-55. PMC: 2744824. DOI: 10.1007/s00125-009-1472-y. View

14.

Astrup A, Rossner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M . Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009; 374(9701):1606-16. DOI: 10.1016/S0140-6736(09)61375-1. View

15.

Montanya E, Sesti G . A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clin Ther. 2010; 31(11):2472-88. DOI: 10.1016/j.clinthera.2009.11.034. View

16.

Seino Y, Rasmussen M, Nishida T, Kaku K . Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr Med Res Opin. 2010; 26(5):1013-22. DOI: 10.1185/03007991003672551. View

17.

Yang W, Chen L, Ji Q, Liu X, Ma J, Tandon N . Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized,.... Diabetes Obes Metab. 2010; 13(1):81-8. DOI: 10.1111/j.1463-1326.2010.01323.x. View

18.

Gaspari T, Liu H, Welungoda I, Hu Y, Widdop R, Knudsen L . A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model. Diab Vasc Dis Res. 2011; 8(2):117-24. DOI: 10.1177/1479164111404257. View

19.

Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean M . Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2011; 36(6):843-54. PMC: 3374073. DOI: 10.1038/ijo.2011.158. View

20.

Henry R, Buse J, Sesti G, Davies M, Jensen K, Brett J . Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program. Endocr Pract. 2011; 17(6):906-13. DOI: 10.4158/ep.17.6.906. View